Outcome measures
post-ET
MISCARRIAGE, ADVERSE EFFECTS, SECONDARY, MISCARRIAGE
The primary endpoints included the clinical pregnancy rate. The secondary endpoints included positive pregnancy test rate, ongoing pregnancy rate, tolerance rate, miscarriage rate, medication cost, and presence of adverse effects such as derangement in aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) parameters.In this study, we defined clinical pregnancy at the ultrasound scan completed at 6 weeks showing the presence of a viable fetus. Miscarriage is the loss of a fetus before the 20Biochemical pregnancy was defined as serum β-hCG level presence on day 15 post-ET, while clinical pregnancy was confirmed by ultrasound detection of a viable fetus at 6 weeks post-ET. The aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) parameters were assessed pre-and post-therapy for monitoring adverse effects.